{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:58:12Z","timestamp":1791863892489,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The efficacy of cabergoline in Cushing\u2019s disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We conducted a retrospective multicenter study from thirteen French and Belgian university hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-two patients with CD received cabergoline monotherapy or add-on therapy. Symptom score, biological markers of hypercortisolism and adverse effects were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-one (40%) of 53 patients who received cabergoline monotherapy had normal urinary free cortisol (UFC) values within 12 months (complete responders), and five of these patients developed corticotropic insufficiency. The fall in UFC was associated with significant reductions in midnight cortisol and plasma ACTH, and with clinical improvement. Compared to other patients, complete responders had similar median baseline UFC (2.0 vs 2.5xULN) and plasma prolactin concentrations but received lower doses of cabergoline (1.5 vs 3.5\u2009mg\/week,\n                      <jats:italic>P\u2009&lt;\u2009<\/jats:italic>\n                      0.05). During long-term treatment (&gt;12 months), cabergoline was withdrawn in 28% of complete responders because of treatment escape or intolerance. Overall, sustained control of hypercortisolism was obtained in 23% of patients for 32.5 months (19\u2013105). Nine patients on steroidogenesis inhibitors received cabergoline add-on therapy for 19 months (1\u2013240). Hypercortisolism was controlled in 56% of these patients during the first year of treatment with cabergoline at 1.0\u2009mg\/week (0.5\u20133.5).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>About 20\u201325% of CD patients are good responders to cabergoline therapy allowing long-term control of hypercortisolism at relatively low dosages and with acceptable tolerability. No single parameter, including the baseline UFC and prolactin levels, predicted the response to cabergoline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eje-16-0662","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T20:57:30Z","timestamp":1482440250000},"page":"305-314","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":104,"title":["Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study"],"prefix":"10.1093","volume":"176","author":[{"given":"A","family":"Ferriere","sequence":"first","affiliation":[{"name":"1CHU BordeauxH\u00f4pital Haut-L\u00e9v\u00eaque, Service d\u2019Endocrinologie, Diab\u00e9tologie et Nutrition, Pessac, France or INSERM U862, Neurocentre Magendie, Universit\u00e9 Bordeaux, Bordeaux Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cortet","sequence":"additional","affiliation":[{"name":"2CHRU LilleService d\u2019Endocrinologie, Diab\u00e9tologie et M\u00e9tabolisme, Lille Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Chanson","sequence":"additional","affiliation":[{"name":"3Assistance Publique-H\u00f4pitaux de ParisH\u00f4pitaux universitaires Paris-Sud, H\u00f4pital de Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Delemer","sequence":"additional","affiliation":[{"name":"4CHU ReimsH\u00f4pital Robert Debr\u00e9, Service d\u2019Endocrinologie, Diab\u00e9tologie et Nutrition, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Caron","sequence":"additional","affiliation":[{"name":"5CHU ToulouseH\u00f4pital Larrey, Service d\u2019Endocrinologie, Maladies M\u00e9taboliques et Nutrition, Toulouse cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Chabre","sequence":"additional","affiliation":[{"name":"6CHU Grenoble AlpesService d\u2019Endocrinologie-Diab\u00e9tologie, Boulevard de la Chantourne, La Tronche, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Reznik","sequence":"additional","affiliation":[{"name":"7CHU CaenService d\u2019Endocrinologie-Diab\u00e9tologie, CAEN cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bertherat","sequence":"additional","affiliation":[{"name":"8Assistance Publique-H\u00f4pitaux de ParisH\u00f4pitaux universitaires Paris-Centre, H\u00f4pital Cochin, Service d\u2019Endocrinologie et Maladies M\u00e9taboliques, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Rohmer","sequence":"additional","affiliation":[{"name":"9CHU AngersD\u00e9partement d\u2019Endocrinologie-Diab\u00e9tologie-Nutrition, Angers Cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Briet","sequence":"additional","affiliation":[{"name":"9CHU AngersD\u00e9partement d\u2019Endocrinologie-Diab\u00e9tologie-Nutrition, Angers Cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Raingeard","sequence":"additional","affiliation":[{"name":"10CHU MontpellierService d\u2019Endocrinologie, Diab\u00e8te, Maladies m\u00e9taboliques, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Castinetti","sequence":"additional","affiliation":[{"name":"11Assistance Publique-H\u00f4pitaux de MarseilleH\u00f4pital de la Conception, Service d\u2019Endocrinologie, Diab\u00e8tes et Maladies M\u00e9taboliques, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Beckers","sequence":"additional","affiliation":[{"name":"12CHU Li\u00e8geService d\u2019Endocrinologie, Domaine Universitaire du Sart Tilman, Li\u00e8ge, Belgique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Vroonen","sequence":"additional","affiliation":[{"name":"12CHU Li\u00e8geService d\u2019Endocrinologie, Domaine Universitaire du Sart Tilman, Li\u00e8ge, Belgique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Maiter","sequence":"additional","affiliation":[{"name":"13Clinique Universitaire Saint LucService d\u2019Endocrinologie et de Nutrition, Bruxelles, Belgique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F L","family":"Cephise-Velayoudom","sequence":"additional","affiliation":[{"name":"14CHU Pointe \u00e0 PitreService d\u2019Endocrinologie, Pointe \u00e0 Pitre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M L","family":"Nunes","sequence":"additional","affiliation":[{"name":"1CHU BordeauxH\u00f4pital Haut-L\u00e9v\u00eaque, Service d\u2019Endocrinologie, Diab\u00e9tologie et Nutrition, Pessac, France or INSERM U862, Neurocentre Magendie, Universit\u00e9 Bordeaux, Bordeaux Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Haissaguerre","sequence":"additional","affiliation":[{"name":"1CHU BordeauxH\u00f4pital Haut-L\u00e9v\u00eaque, Service d\u2019Endocrinologie, Diab\u00e9tologie et Nutrition, Pessac, France or INSERM U862, Neurocentre Magendie, Universit\u00e9 Bordeaux, Bordeaux Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tabarin","sequence":"additional","affiliation":[{"name":"1CHU BordeauxH\u00f4pital Haut-L\u00e9v\u00eaque, Service d\u2019Endocrinologie, Diab\u00e9tologie et Nutrition, Pessac, France or INSERM U862, Neurocentre Magendie, Universit\u00e9 Bordeaux, Bordeaux Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2017010918302795000_176.3.305.1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3582"},{"key":"2017010918302795000_176.3.305.2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818"},{"key":"2017010918302795000_176.3.305.3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3200"},{"key":"2017010918302795000_176.3.305.4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0382"},{"key":"2017010918302795000_176.3.305.5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030837"},{"key":"2017010918302795000_176.3.305.6","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1210\/jc.2013-1987","article-title":"Preoperative normalization of cortisol levels in Cushing\u2019s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists","volume":"98","author":"Van der Pas","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2017010918302795000_176.3.305.7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1533"},{"key":"2017010918302795000_176.3.305.8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0209-8"},{"key":"2017010918302795000_176.3.305.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0475-3"},{"key":"2017010918302795000_176.3.305.10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-15-0807","article-title":"Limited value of cabergoline in Cushing\u2019s disease: a prospective study of a 6-week treatment in 20 patients","volume":"174","author":"Burman","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"2017010918302795000_176.3.305.11","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijo.0802215","article-title":"Updated review on the benefits of weight loss","volume":"26","author":"Vidal","year":"2002","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"2017010918302795000_176.3.305.12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2387"},{"key":"2017010918302795000_176.3.305.13","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282f0580f"},{"key":"2017010918302795000_176.3.305.14","first-page":"233","article-title":"The defined daily dose system (DDD) for drug utilization review","volume":"21","author":"Wertheimer","year":"1986","journal-title":"Hospital Pharmacy"},{"key":"2017010918302795000_176.3.305.15","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050064"},{"key":"2017010918302795000_176.3.305.16","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-13-2-220"},{"key":"2017010918302795000_176.3.305.17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/BF03343983","article-title":"Macroprolactinoma associated with Cushing\u2019s disease, successfully treated with cabergoline","volume":"25","author":"T\u2019Sjoen","year":"2002","journal-title":"Journal of Endocrinological Investigation"},{"key":"2017010918302795000_176.3.305.18","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1440051"},{"key":"2017010918302795000_176.3.305.19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11102-011-0309-0","article-title":"Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report","volume":"15","author":"Manavela","year":"2012","journal-title":"Pituitary"},{"key":"2017010918302795000_176.3.305.20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.4.1163"},{"key":"2017010918302795000_176.3.305.21","doi-asserted-by":"publisher","DOI":"10.4158\/EP10031.OR"},{"key":"2017010918302795000_176.3.305.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1000094"},{"key":"2017010918302795000_176.3.305.23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3628"},{"key":"2017010918302795000_176.3.305.24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2616"},{"key":"2017010918302795000_176.3.305.25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/cen.12207","article-title":"Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.","volume":"79","author":"Howlett","year":"2013","journal-title":"Clinical Endocrinology"},{"key":"2017010918302795000_176.3.305.26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0322"},{"key":"2017010918302795000_176.3.305.27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443"},{"key":"2017010918302795000_176.3.305.28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2603"},{"key":"2017010918302795000_176.3.305.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105743"},{"key":"2017010918302795000_176.3.305.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2005.02.001"},{"key":"2017010918302795000_176.3.305.31","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.12"},{"key":"2017010918302795000_176.3.305.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04172-6"},{"key":"2017010918302795000_176.3.305.33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2137"},{"key":"2017010918302795000_176.3.305.34","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01959"},{"key":"2017010918302795000_176.3.305.35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000987"},{"key":"2017010918302795000_176.3.305.36","unstructured":"Bertagna X Raux-Demay MC Guilhaume B Girard F Luton JP . Cushing\u2019s disease. In The Pituitary, edn 2, pp 478\u2013545. Eds Melmed S . Los Angeles, CA, USA: Blackwell Science, 1995."},{"key":"2017010918302795000_176.3.305.37","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12259"},{"key":"2017010918302795000_176.3.305.38","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1048"},{"key":"2017010918302795000_176.3.305.39","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0913"},{"key":"2017010918302795000_176.3.305.40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","article-title":"Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study","volume":"4","author":"Clayton","year":"2016","journal-title":"Lancet Diabetes Endocrinology"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/176\/3\/305.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-16-0662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:02:52Z","timestamp":1718953372000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/176\/3\/305\/6655130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":40,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/eje-16-0662","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}